CT:IQ Welcomes Alexion to the Steering Committee

We are delighted to announce that Alexion, AstraZeneca Rare Disease, ANZ has joined CTIQ’s Steering Committee as our newest member.

Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities.

Alexion’s mission to innovate and create meaningful value aligns well with CT:IQ’s goal of improving the clinical trials sector. With their expertise and dedication to patient communities, Alexion brings invaluable insights and a strong collaborative spirit to our work.

We look forward to the impact we can achieve together, driving innovation and making a real difference in the lives of patients and the clinical trials community. Welcome, Alexion!